A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.

IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s - POTOMAC, MD / ACCESS Newswire / March ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

Cognition may be just one phase of intelligence—as AI evolves, thought itself begins to dissolve into something more fluid, ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...

Alzheimer’s is a progressive neurological disorder that affects memory, thinking, and behavior. It worsens over time, leading ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

A new study uncovers compelling evidence that even subtle heart issues may affect brain structure — potentially years before ...

The science-backed supplement is a must for building strength and muscle, but is there an optimal time to take it?

Significant updates included announcement of the 100-day timeline for Alzheimer's trial results and progress in the RDEB program. These developments marked a shift from the previous quarter's focus on ...